Neogen (FRA:NG2) Non Operating Income: € Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG2 Neogen Corp FRA:NG2
68 GF Score
Price €11.03
GF Value €9.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Neogen Non Operating Income?

Neogen FRA:NG2 +2.18% 68 Non Operating Income is € Mil as of May. 2026. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €9.83 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Neogen's Non Operating Income for the three months ended in May. 2026 was € Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 was € Mil.

Neogen Non Operating Income Related Terms

Neogen Non Operating Income Historical Data

* Premium members only.

The historical data trend for Neogen's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neogen Non Operating Income Chart

Neogen Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neogen Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:NG2
68GF Score
Neogen Corp FRA:NG2
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neogen Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was € Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of € Mil mean?
Neogen (FRA:NG2) has a Non Operating Income of € Mil as of May. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Neogen and its competitors.
Is Neogen's Non Operating Income too high?
Neogen's current Non Operating Income is € Mil. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Non Operating Income compare to UFPT and AXGN?
Neogen's Non Operating Income of € Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Devices & Instruments company?
A good Non Operating Income depends on the Medical Devices & Instruments industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Neogen and its competitors. Neogen's current Non Operating Income is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.83, compared to a current price of €11.03 — trading 12.2% above its estimated fair value. The current Non Operating Income is € Mil. Neogen's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Non Operating Income is € Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neogen (FRA:NG2) Overvalued in 2026?

Based on GuruFocus' analysis, Neogen stock appears to be overvalued. The current stock price of €11.03 is trading 12.2% above its estimated GF Value™ of €9.83. GuruFocus considers Neogen to be Modestly Overvalued.

Key valuation signals for FRA:NG2:

  • Non Operating Income: € Mil
  • GF Value™: €9.83 vs. price of €11.03 (12.2% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neogen Business Description

Other Exchanges NEOG:USANG2:Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score

Get the complete analysis for FRA:NG2

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.03
Price
€9.83
GF Value